One operation or two — the decision that shapes everything

For many patients, the most pressing question is not which cells are used or how the scaffold works — it is simply: how many times will I need a general anaesthetic? The answer differs sharply between the two approaches, and that difference shapes everything from time off work to the psychological weight of treatment.

Traditional ACI unfolds across two separate operations. On the first visit, a surgeon removes a small sliver of healthy cartilage through an arthroscope — a keyhole procedure lasting less than an hour. That biopsy is then dispatched to a specialist laboratory, where chondrocytes are cultured and multiplied over four to six weeks. Only once sufficient cells have grown is the patient recalled for Stage 2: a second operation, a second general anaesthetic, and a second full recovery, during which the cultured cells are implanted into the defect under a periosteal patch.

STACI compresses both stages into a single theatre session. The laboratory step moves into the operating room: while the surgeon prepares the defect site, an intraoperative lab team processes the harvested cells immediately. The result is one procedure, one recovery period, and no weeks-long wait between biopsy and repair.

The shared foundation matters: both ACI and STACI rely on the patient's own cartilage cells, so the biological principle — autologous chondrocytes, no rejection risk — is identical. The divergence is in timing and delivery.

One important caveat: STACI does not guarantee a single operation in every case. Whether it proceeds as one stage or two is a clinical decision made after imaging review of the specific defect — it is not a fixed rule of the procedure.

What actually happens inside each procedure

The biology inside each procedure explains why the timelines diverge in the first place.

In two-stage ACI, the harvested cartilage biopsy is shipped to a specialist laboratory, where technicians isolate the chondrocytes and place them in a culture medium. Over four to six weeks the cells divide and multiply until there are enough for reimplantation — that culture period is the reason Stage 2 cannot happen sooner. At Stage 2, the expanded chondrocytes are secured over the prepared defect: in classic ACI beneath a periosteal flap harvested from the shin, or in the modern MACI variant, seeded onto a flat Type I/III collagen membrane that is sutured or glued into place.

STACI takes a different route through the same biology. An intraoperative laboratory team enzymatically digests the cartilage biopsy to free the chondrocytes without altering their character. Simultaneously, bone-marrow aspirate is taken from within the surgical field; mesenchymal stem cells (MSCs) are then concentrated, washed, and counted under a microscope before being combined with the chondrocytes. The mixed cell population is loaded onto a three-dimensional collagen scaffold while the surgeon prepares the defect bed — the entire process unfolding within the same theatre session.

The scaffold geometry is a meaningful distinction. Where MACI uses a flat membrane, STACI's three-dimensional structure supports cell growth in depth as well as across the surface, more closely matching the layered architecture of native cartilage. This is an architectural difference with a biological rationale; direct long-term comparative outcome data between the two scaffold types have not yet been established in randomised trials.

Which defects and joints are suitable for each approach

Defect location, size, and joint condition narrow eligibility more than any other single factor.

Traditional ACI and its modern variant MACI are indicated primarily for focal cartilage defects in the knee, broadly within the 2–10 cm² range — large enough that simpler techniques are likely to underperform, but contained enough that structured cell-based repair is feasible. NHS access for ACI reflects this scope: coverage centres on the knee, for focal full-thickness defects in patients who meet clinical criteria.

STACI covers a wider joint list — knee, hip, shoulder, ankle, and other joints. For patients whose damage lies outside the knee, this distinction carries real weight: standard ACI or MACI is unlikely to be offered at all. STACI can also take on defects that fall outside ACI's treatable range because they are too large or too complex, meaning some patients who would previously have been turned away may now have a cell-based option.

Across both pathways, assessment turns on the condition of the joint rather than the patient's age. Cartilage grade, subchondral bone health, and mechanical alignment are the governing factors. The typical candidate for either procedure is too young or too active to accept a joint replacement and is seeking a joint-preservation route instead.

One boundary holds for both approaches: neither is designed for advanced, diffuse osteoarthritis. Cell-based repair suits focal defects in a joint that retains enough structural integrity to support regeneration. Where degeneration has spread throughout a compartment, the clinical conversation moves in a different direction.

How recovery timelines compare

The two-stage ACI path creates two separate recovery windows. After the arthroscopic biopsy at Stage 1, patients face a short period of reduced activity — manageable, but not trivial. The four-to-six week cell-culture interval that follows is not a rest period: it is time spent arranging a second operation while managing partial limb use. Work absence, childcare, and transport must all be planned twice over.

Stage 2 reimplantation carries the heavier burden. Weight-bearing restrictions and a structured physiotherapy programme begin in earnest at this point, and the rehabilitation arc — returning to demanding activity — unfolds over many months regardless of which cell-based approach was used.

STACI compresses this into one post-operative period. Removing the inter-stage interval eliminates one round of logistical planning and one general anaesthetic, which can meaningfully reduce total disruption to work and daily life. What it does not do is shorten the cartilage maturation process that follows implantation: the rehabilitation timeline is broadly similar across both approaches, and a single-stage procedure should not be read as an overall faster recovery.

Weight-bearing protocols and physiotherapy milestones after implantation are comparable across ACI and STACI. A consultant and physiotherapy team will set the specific schedule based on defect size, joint, and individual progress — no fixed return-to-activity timeline should be assumed for either pathway.

What the evidence shows — and where gaps remain

Traditional ACI carries the deeper evidence base. Published series spanning nine or more years document meaningful pain relief and delay of partial or total joint replacement, and the procedure is guideline-endorsed with NHS access for eligible patients. MACI, the modern scaffold iteration, adds five-year randomised controlled trial data and MRI evidence of defect fill — a body of work that gives two-stage cell-based repair a well-documented clinical footing.

STACI is categorised as a next-generation, emerging technique. The published anchor in the literature is Taylor and Lee (2019), Single Treatment Autologous Chondrocyte Implantation: The Next Generation of ACI, which situates the single-stage approach in the context of what two-stage ACI established. No randomised controlled trial directly comparing STACI with two-stage ACI has been identified — this asymmetry in the evidence base is the first thing worth understanding when weighing the two approaches.

Two further gaps are worth naming. First, the proportion of STACI cases that nevertheless proceed as two stages in clinical practice is not specified in published data — that figure would help patients set realistic expectations about what 'single-stage' means in practice. Second, published cost-comparison data between STACI and standard ACI, including what NHS coverage applies, are not currently available in the literature.

None of these gaps disqualify STACI as a pathway. What they do mean, concretely, is that a specialist consultation should include direct questions about staging likelihood and funding route — two points the current evidence cannot answer in advance of an individual clinical assessment.

Finding a specialist and the questions worth asking

Confirming that a specific surgeon or centre offers STACI is the essential first step — it remains available at a limited number of specialist centres in the UK, and not every cartilage unit delivers it. Two-stage ACI is more widely accessible, including through NHS pathways for qualifying patients; a GP or referring clinician can advise on eligibility.

Before any consultation, MRI imaging and a clinical examination are required to determine whether either pathway is realistic for a given defect — patients cannot reliably self-select a route without that assessment.

Four questions worth bringing to a first appointment:

• Is my defect size and joint suitable for ACI, STACI, or both?
• If STACI is appropriate, would my case proceed in one stage or two?
• What is the realistic total timeline to return to my target activity level?
• Is this procedure available on the NHS in my circumstances?

Search MSK lists cartilage repair specialists across the UK — filter by region and specialty to find a clinician who offers the approach relevant to your situation.